MBBS
TARCEVA 25 MG 30 TABLET
How It Works
TARCEVA contains the active ingredient erlotinib, which is a tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR). EGFR is a protein that is often overexpressed or mutated in certain types of cancer cells, including non-small cell lung cancer (NSCLC) and pancreatic cancer. By inhibiting EGFR, TARCEVA blocks the signaling pathways that promote cancer cell growth, proliferation, and survival. This helps to slow down or stop the growth of cancer cells, leading to tumor shrinkage and improved patient outcomes.
Side Effects
- Rash
- Diarrhea
- Nausea
- Fatigue
- Loss of appetite
- Cough
- Shortness of breath
Indications
- TARCEVA is indicated for the treatment of:
- Non-small cell lung cancer (NSCLC) with certain EGFR mutations
- Pancreatic cancer (in combination with gemcitabine) that has spread to other parts of the body
Contraindications
- Hypersensitivity to erlotinib or any component of the formulation
- Severe hepatic impairment
Price Comparison in Different Countries
| Country | Price (per tablet) | Website |
|---|---|---|
| United States | $150 | GoodRx |
| United Kingdom | £120 | NHS |
| Australia | AUD 180 | Chemist Warehouse |
| Canada | CAD 160 | Canada Drugs Direct |
| Germany | €130 | Apotheken Umschau |
Top 5 Global Brands
- Roche
- Genentech
- Chugai Pharmaceutical Co., Ltd.
- Hoffmann-La Roche Ltd.
- Roche Diagnostics
One of the following licensed pharmacy from the nearest location will deliver TARCEVA 25 MG 30 TABLET. The details of the licensed pharmacy shall be shared once you request the drugs and the respective pharmacy accepts your request based on valid prescription and availability.
Questions and Answers
There are no questions yet. Be the first to ask a question about this product.
Reviews
There are no reviews yet.